U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Clinical trial considerations to support Accelerated Approval of oncology therapeutics: guidance for industry. fda.gov, https://www.fda.gov/media/166431/download (2023).

Jones, C. The Best of 2022: FDA approvals and the breakthroughs that enabled them. Cancer research catalyst. aacr.org, https://www.aacr.org/blog/2022/12/30/the-best-of-2022-fda-approvals-and-the-breakthroughs-that-enabled-them/ (2022).

US Food and Drug Administration. Withdrawn | Cancer Accelerated Approvals. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals (2023).

Parikh, R. B. et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration Accelerated Approval. JAMA Oncol. 9, 567–569 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).

Article  PubMed  Google Scholar 

Gloy, V. et al. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. Int. J. Cancer 152, 2474–2484 (2023).

Article  CAS  PubMed  Google Scholar 

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. fda.gov, https://www.fda.gov/media/71195/download (2018).

Kim, C. & Prasad, V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern. Med. 175, 1992–1994 (2015).

Article  PubMed  Google Scholar 

Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012).

Article  CAS  PubMed  Google Scholar 

Office of Inspector General, U.S. Department of Health and Human Services. Delays in confirmatory trials for drug applications granted FDA’s Accelerated Approval raises concerns. oig.hhs.gov, https://oig.hhs.gov/oei/reports/OEI-01-21-00401.asp (2022).